Glycemic control of type 2 diabetic patients with coronavirus disease during hospitalization: a proposal for early insulin therapy

Am J Physiol Endocrinol Metab. 2020 Jun 1;318(6):E835-E837. doi: 10.1152/ajpendo.00163.2020.
No abstract available

Publication types

  • Letter

MeSH terms

  • Angiotensin-Converting Enzyme 2
  • Animals
  • Blood Glucose / drug effects
  • Blood Glucose / metabolism*
  • COVID-19
  • Coronavirus Infections / blood
  • Coronavirus Infections / complications
  • Coronavirus Infections / epidemiology
  • Coronavirus Infections / therapy*
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / epidemiology
  • Diabetes Mellitus, Type 2 / therapy*
  • Drug Administration Schedule
  • Early Medical Intervention / methods
  • Early Medical Intervention / standards
  • Glycated Hemoglobin / drug effects
  • Glycated Hemoglobin / metabolism
  • Hospitalization*
  • Humans
  • Hypoglycemic Agents / administration & dosage
  • Insulin / administration & dosage*
  • Mice
  • Mice, Knockout
  • Pandemics
  • Peptidyl-Dipeptidase A / physiology*
  • Peptidyl-Dipeptidase A / therapeutic use
  • Peptidyl-Dipeptidase A / urine
  • Pneumonia, Viral / blood
  • Pneumonia, Viral / complications
  • Pneumonia, Viral / epidemiology
  • Pneumonia, Viral / therapy*
  • Recombinant Proteins / therapeutic use
  • Time Factors

Substances

  • Blood Glucose
  • Glycated Hemoglobin A
  • Hypoglycemic Agents
  • Insulin
  • Recombinant Proteins
  • hemoglobin A1c protein, human
  • Peptidyl-Dipeptidase A
  • ACE2 protein, human
  • Ace2 protein, mouse
  • Angiotensin-Converting Enzyme 2